Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine
Zika virus (ZIKV) infections are spreading silently with limited global surveillance in at least 89 countries and territories. There is a pressing need to develop an effective vaccine suitable for equitable distribution globally. Consequently, we previously developed a proprietary DNA vaccine encodi...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Molecular Therapy: Nucleic Acids |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253123002743 |
| _version_ | 1797648352215564288 |
|---|---|
| author | Danushka K. Wijesundara Arthur Yeow Christopher L.D. McMillan Jovin J.Y. Choo Aleksandra Todorovic Zelalem A. Mekonnen Makutiro G. Masavuli Paul R. Young Eric J. Gowans Branka Grubor-Bauk David A. Muller |
| author_facet | Danushka K. Wijesundara Arthur Yeow Christopher L.D. McMillan Jovin J.Y. Choo Aleksandra Todorovic Zelalem A. Mekonnen Makutiro G. Masavuli Paul R. Young Eric J. Gowans Branka Grubor-Bauk David A. Muller |
| author_sort | Danushka K. Wijesundara |
| collection | DOAJ |
| description | Zika virus (ZIKV) infections are spreading silently with limited global surveillance in at least 89 countries and territories. There is a pressing need to develop an effective vaccine suitable for equitable distribution globally. Consequently, we previously developed a proprietary DNA vaccine encoding secreted non-structural protein 1 of ZIKV (pVAX-tpaNS1) to elicit rapid protection in a T cell-dependent manner in mice. In the current study, we evaluated the stability, efficacy, and immunogenicity of delivering this DNA vaccine into the skin using a clinically effective and proprietary high-density microarray patch (HD-MAP). Dry-coating of pVAX-tpaNS1 on the HD-MAP device resulted in no loss of vaccine stability at 40°C storage over the course of 28 days. Vaccination of mice (BALB/c) with the HD-MAP-coated pVAX-tpaNS1 elicited a robust anti-NS1 IgG response in both the cervicovaginal mucosa and systemically and afforded protection against live ZIKV challenge. Furthermore, the vaccination elicited a significantly higher magnitude and broader NS1-specific T helper and cytotoxic T cell response in vivo compared with traditional needle and syringe intradermal vaccination. Overall, the study highlights distinctive immunological advantages coupled with an excellent thermostability profile of using the HD-MAP device to deliver a novel ZIKV DNA vaccine. |
| first_indexed | 2024-03-11T15:31:00Z |
| format | Article |
| id | doaj.art-3a57796828b4448fb11999e2970c3e10 |
| institution | Directory Open Access Journal |
| issn | 2162-2531 |
| language | English |
| last_indexed | 2024-03-11T15:31:00Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Nucleic Acids |
| spelling | doaj.art-3a57796828b4448fb11999e2970c3e102023-10-27T04:24:04ZengElsevierMolecular Therapy: Nucleic Acids2162-25312023-12-0134102056Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccineDanushka K. Wijesundara0Arthur Yeow1Christopher L.D. McMillan2Jovin J.Y. Choo3Aleksandra Todorovic4Zelalem A. Mekonnen5Makutiro G. Masavuli6Paul R. Young7Eric J. Gowans8Branka Grubor-Bauk9David A. Muller10Vaxxas Biomedical Facility, Hamilton, QLD 4007, Australia; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia; Corresponding author: Danushka K. Wijesundara, Vaxxas Biomedical Facility, Hamilton, QLD 4007, Australia.Discipline of Surgery, The University of Adelaide, Basil Hetzel Institute for Translational Health Research, Adelaide, SA 5005, AustraliaSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, AustraliaSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, AustraliaSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, AustraliaDiscipline of Surgery, The University of Adelaide, Basil Hetzel Institute for Translational Health Research, Adelaide, SA 5005, AustraliaDiscipline of Surgery, The University of Adelaide, Basil Hetzel Institute for Translational Health Research, Adelaide, SA 5005, AustraliaSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, AustraliaDiscipline of Surgery, The University of Adelaide, Basil Hetzel Institute for Translational Health Research, Adelaide, SA 5005, AustraliaDiscipline of Surgery, The University of Adelaide, Basil Hetzel Institute for Translational Health Research, Adelaide, SA 5005, Australia; Corresponding author: Branka Grubor-Bauk, Discipline of Surgery, The University of Adelaide, Basil Hetzel Institute for Translational Health Research, Adelaide, SA 5005, Australia.Vaxxas Biomedical Facility, Hamilton, QLD 4007, Australia; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia; Corresponding author: David A. Muller, Vaxxas Biomedical Facility, Hamilton, QLD 4007, Australia.Zika virus (ZIKV) infections are spreading silently with limited global surveillance in at least 89 countries and territories. There is a pressing need to develop an effective vaccine suitable for equitable distribution globally. Consequently, we previously developed a proprietary DNA vaccine encoding secreted non-structural protein 1 of ZIKV (pVAX-tpaNS1) to elicit rapid protection in a T cell-dependent manner in mice. In the current study, we evaluated the stability, efficacy, and immunogenicity of delivering this DNA vaccine into the skin using a clinically effective and proprietary high-density microarray patch (HD-MAP). Dry-coating of pVAX-tpaNS1 on the HD-MAP device resulted in no loss of vaccine stability at 40°C storage over the course of 28 days. Vaccination of mice (BALB/c) with the HD-MAP-coated pVAX-tpaNS1 elicited a robust anti-NS1 IgG response in both the cervicovaginal mucosa and systemically and afforded protection against live ZIKV challenge. Furthermore, the vaccination elicited a significantly higher magnitude and broader NS1-specific T helper and cytotoxic T cell response in vivo compared with traditional needle and syringe intradermal vaccination. Overall, the study highlights distinctive immunological advantages coupled with an excellent thermostability profile of using the HD-MAP device to deliver a novel ZIKV DNA vaccine.http://www.sciencedirect.com/science/article/pii/S2162253123002743MT: Delivery Strategiesskin patchHD-MAPT cell immunitycytotoxic T cellsnon-structural protein 1 |
| spellingShingle | Danushka K. Wijesundara Arthur Yeow Christopher L.D. McMillan Jovin J.Y. Choo Aleksandra Todorovic Zelalem A. Mekonnen Makutiro G. Masavuli Paul R. Young Eric J. Gowans Branka Grubor-Bauk David A. Muller Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine Molecular Therapy: Nucleic Acids MT: Delivery Strategies skin patch HD-MAP T cell immunity cytotoxic T cells non-structural protein 1 |
| title | Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine |
| title_full | Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine |
| title_fullStr | Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine |
| title_full_unstemmed | Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine |
| title_short | Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine |
| title_sort | superior efficacy of a skin applied microprojection device for delivering a novel zika dna vaccine |
| topic | MT: Delivery Strategies skin patch HD-MAP T cell immunity cytotoxic T cells non-structural protein 1 |
| url | http://www.sciencedirect.com/science/article/pii/S2162253123002743 |
| work_keys_str_mv | AT danushkakwijesundara superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT arthuryeow superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT christopherldmcmillan superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT jovinjychoo superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT aleksandratodorovic superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT zelalemamekonnen superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT makutirogmasavuli superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT paulryoung superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT ericjgowans superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT brankagruborbauk superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine AT davidamuller superiorefficacyofaskinappliedmicroprojectiondevicefordeliveringanovelzikadnavaccine |